Tuesday, Dec 10, 1991
South San Francisco, Calif. -- December 10, 1991 --Genentech, Inc. (NYSE: GNE) today announced that The Wellcome Foundation Ltd. and Sandoz Pharma Ltd. each have licensed rights under a basic Genentech patent covering recombinant chimeric immunoglobulins and the manufacturing methods to make them.
Wellcome and Sandoz licensed rights under U.S. Patent No. 4,816,567 to commercially develop antibodies which bind to specific antigens. The licenses are part of a program previously announced by Genentech to grant a limited number of co-exclusive licenses for antibodies directed toward select antigen targets. This program is ongoing, but Genentech expects to soon grant all of the available licenses for certain antigens.
The U.S. Patent Office earlier this year declared an interference between a related pending Genentech patent application and an issued patent assigned to Celltech Ltd. (U.S. 4,816,397). This pending Genentech patent applications is directed to the coexpression of immunoglobulin chains including, but not restricted to, chimeric immunoglobulins.
Immunoglobulins are antibodies which have a major role in the body's natural defense against disease. The rights available for license under Genentech's program cover methodologies basic to making these recombinant drugs.
Additional information is available from Michael Johnson, Genentech manager of business development.
Genentech, Inc. is a biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant medical needs.
# # #